LABORATORY MODELS OF COCAINE SELF ADMINISTRATION
可卡因自我给药的实验室模型
基本信息
- 批准号:8166772
- 负责人:
- 金额:$ 2.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-12-01 至 2010-11-30
- 项目状态:已结题
- 来源:
- 关键词:Admission activityAdverse eventClinical TrialsCocaineCocaine DependenceComputer Retrieval of Information on Scientific Projects DatabaseDevelopmentDisulfiramDoseDouble-Blind MethodEnrollmentExclusion CriteriaFundingGrantHumanInformed ConsentInpatientsInstitutionLaboratoriesMedical centerModelingOutcomeOutpatientsParticipantPharmaceutical PreparationsPhasePlacebo ControlPlacebosPredictive ValueProcessPublishingRandomizedResearchResearch PersonnelResourcesScreening procedureSelf AdministrationSourceStudy SubjectUnited States National Institutes of HealthVisitcocaine usedesigneffective therapypaymenttreatment effectvolunteer
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
After completing the informed consent process, potential volunteers will complete outpatient screening, including assessment of inclusion/exclusion criteria. This will be a double-blind, placebo-controlled, within-subjects study. The study will be conducted in 20 non-treatment seeking cocaine (COC)-dependent subjects who will reside in the Michael De Bakey VA Medical Center during two separate 5-day visits.
After admission and stabilization (day 1), participants will be randomly assigned to placebo or disulfiram (250mg qd). Participants will take the study drug on days 2-4. On day 4, participants will participate in two COC self-administration in which they will have the opportunity to choose between COC (0 and 20 mg, IV) or money alternatives. On day 5, participants will be discharged from the study and will return a minimum of 7 days for enrollment and randomization to alternate disulfiram dosing conditions. During the 2nd inpatient phase, participants will receive payment for prior enrollment and staff will assess late emerging adverse events. Participants will receive payments of $50 per day provided they abstain from illicit cocaine use.
We anticipate that disulfiram treatment will be associated with reduced cocaine self-administration. Results of the proposed research will provide information about the predictive value of two different laboratory models of cocaine self-administration. If results from either or both of these laboratory models are congruent with outcomes from published clinical trials of disulfiram, then further research aimed at optimizing design parameters would be indicated to further develop these approaches. The development of valid laboratory models would greatly facilitate the search for more effective treatments for cocaine dependence.
To determine the effects of treatment with disulfiram on cocaine self-administration using a human laboratory model of cocaine self-administration.
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
在完成知情同意程序后,潜在志愿者将完成门诊筛查,包括评估纳入/排除标准。这将是一项双盲、安慰剂对照、受试者内的研究。这项研究将在20名非治疗寻求可卡因(COC)依赖的受试者中进行,他们将在Michael de Bakey VA医疗中心分别进行两次为期5天的访问。
在入院和稳定后(第1天),参与者将被随机分配给安慰剂或双硫仑(250 mg,qd)。参与者将在第2-4天服用学习药物。在第4天,参与者将参加两次COC自我管理,他们将有机会在COC(0和20 mg,IV)或Money替代品之间进行选择。在第5天,参与者将从研究中出院,并将返回至少7天的登记和随机到替代的双硫仑剂量条件。在第二个住院阶段,参与者将收到先前登记的费用,工作人员将评估后期出现的不良事件。参与者将获得每天50美元的报酬,前提是他们不使用非法可卡因。
我们预计,双硫兰治疗将与减少可卡因的自我给药有关。拟议的研究结果将提供关于两种不同的可卡因自我给药实验室模型的预测价值的信息。如果这两个实验室模型中的一个或两个的结果与已公布的双硫仑临床试验的结果一致,则应进行旨在优化设计参数的进一步研究,以进一步开发这些方法。开发有效的实验室模型将极大地促进寻找更有效的可卡因依赖治疗方法。
利用可卡因自身给药的人体实验室模型,确定双硫仑治疗对可卡因自我给药的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas Frederick Newton其他文献
Thomas Frederick Newton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas Frederick Newton', 18)}}的其他基金
Triple Re-uptake Inhibitor, SKL 10406, as a New Treatment for Alcohol Dependence
三重再摄取抑制剂 SKL 10406,作为酒精依赖的新治疗方法
- 批准号:
8834162 - 财政年份:2015
- 资助金额:
$ 2.67万 - 项目类别:
Carisbamate Treatment for Alcohol Dependence
Carisbamate 治疗酒精依赖
- 批准号:
8735477 - 财政年份:2013
- 资助金额:
$ 2.67万 - 项目类别:
Carisbamate Treatment for Alcohol Dependence
Carisbamate 治疗酒精依赖
- 批准号:
8455440 - 财政年份:2013
- 资助金额:
$ 2.67万 - 项目类别:
Carisbamate Treatment for Alcohol Dependence
Carisbamate 治疗酒精依赖
- 批准号:
8900485 - 财政年份:2013
- 资助金额:
$ 2.67万 - 项目类别:
Clinical Research Education for Drug Abuse Professionals
药物滥用专业人员的临床研究教育
- 批准号:
8231271 - 财政年份:2011
- 资助金额:
$ 2.67万 - 项目类别:
Clinical Research Education for Drug Abuse Professionals
药物滥用专业人员的临床研究教育
- 批准号:
8433405 - 财政年份:2011
- 资助金额:
$ 2.67万 - 项目类别:
Clinical Research Education for Drug Abuse Professionals
药物滥用专业人员的临床研究教育
- 批准号:
8624682 - 财政年份:2011
- 资助金额:
$ 2.67万 - 项目类别:
Clinical Research Education for Drug Abuse Professionals
药物滥用专业人员的临床研究教育
- 批准号:
7861881 - 财政年份:2011
- 资助金额:
$ 2.67万 - 项目类别:
N-ACETYLCYSTEINE AS A POTENTIAL TREATMENT FOR METHAMPHETAMINE DEPENDENCE
N-乙酰半胱氨酸作为甲基苯丙胺依赖的潜在治疗方法
- 批准号:
8356780 - 财政年份:2010
- 资助金额:
$ 2.67万 - 项目类别:
THE EFFECTS OF DOXAZOSIN ON THE CARDIOVASCULAR AND SUBJECTIVE EFFECTS OF COCAINE
多沙唑嗪对心血管的影响和可卡因的主观影响
- 批准号:
8356781 - 财政年份:2010
- 资助金额:
$ 2.67万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 2.67万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 2.67万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 2.67万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 2.67万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 2.67万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 2.67万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 2.67万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 2.67万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 2.67万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 2.67万 - 项目类别: